id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-271998-hdkmwihu	Rabenau, H. F.	SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation	2005-06-30		.txt	text/plain	3071	170	49	SARS-CoV viraemia does not seem to reach high titres, however, it has to be excluded that virus transmission may occur via blood transfusion or application of therapeutic plasma products, e.g. fresh-frozen plasma or single components derived thereof. On the basis of existing validation data for enveloped viruses, it can be anticipated that the inactivation/ removal steps incorporated into manufacturing processes for plasma-derived medicinal products will also be effective for SARS-CoV. Therefore, the inactivation of SARS-CoV by SD treatment was investigated in the laboratory scale at lowered concentration of solvent and detergent (75% of standard SD concentration) and at a shortened process time (30 min). In conclusion, the results obtained in our investigation demonstrated that the process conditions specified for the SD treatment of OCTAGAM are very sufficient to inactivate enveloped viruses such as SARS-CoV to below the limit of detection.	./cache/cord-271998-hdkmwihu.txt	./txt/cord-271998-hdkmwihu.txt